Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources
Cancer Biomarkers Research Group

Publications

View All  |  2014-2010  |  2009-2003

2014

2013

  • Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J, Wei JT, Thompson IM. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator. J Urol. 2013 Jul;190(1):70-6. Epub 2013 Jan 9.
    [ PubMed Abstract ]
  • Dunn BK, Srivastava S, Kramer BS. The word "cancer": how language can corrupt thought. BMJ. 2013 Sep 10;347.
    [ PubMed Abstract ]
  • Feng Z, Kagan J, Pepe M, Thornquist M, Ann Rinaudo J, Dahlgren J, Krueger K, Zheng Y, Patriotis C, Huang Y, Sorbara L, Thompson I, Srivastava S. The Early Detection Research Network's Specimen reference sets: paving the way for rapid evaluation of potential biomarkers Clin Chem. 2013 Jan;59(1):68-74. Epub 2012 Nov 27.
    [ PubMed Abstract ]
  • Pepper JA, Vydelingum NA, Dunn BK, FagerstromRM: Agent-Based Models in Cancer Prevention Research; in Agent-Based Models: Theory, Developments & Applications, (pp 105-116) Exit Disclaimer. Nova Science Publishers, Hauppauge, New York.
  • Shi T, Fillmore TL, Gao Y, Zhao R, He J, Schepmoes AA, Nicora CD, Wu C, Chambers JL, Moore RJ, Kagan J, Srivastava S, Liu AY, Rodland KD, Liu T, Camp DG 2nd, Smith RD, Qian WJ. Long-gradient separations coupled with selected reaction monitoring for highly sensitive, large scale targeted protein quantification in a single analysis. Anal Chem. 2013 Oct 1;85(19):9196-203. Epub 2013 Sep 19.
    [ PubMed Abstract ]
  • Shi T, Gao Y, Quek SI, Fillmore TL, Nicora CD, Su D, Zhao R, Kagan J, Srivastava S, Rodland KD, Liu T, Smith RD, Chan DW, Camp DG 2nd, Liu AY, Qian WJ. A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. J Proteome Res. 2013 Dec 3. [Epub ahead of print]
    [ PubMed Abstract ]
  • Shi T, Sun X, Gao Y, Fillmore TL, Schepmoes AA, Zhao R, He J, Moore RJ, Kagan J, Rodland KD, Liu T, Liu AY, Smith RD, Tang K, Camp DG 2nd, Qian WJ.J Targeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletion. Proteome Res. 2013 Jul 5;12(7):3353-61. Epub 2013 Jun 13.
    [ PubMed Abstract ]
  • Srivastava S. Early Detection Research Network: 10-year outlook. Clin Chem. 2013 Jan;59(1):60-7.
    [ PubMed Abstract ]
  • Vydelingum NA, Sorbara L, Wagner P, Srivastava S. Standards in molecular diagnostics for the discovery and validation of clinically useful cancer biomarkers. Expert Rev Mol Diagn. 2013 Jun;13(5):421-3.
    [ PubMed Abstract ]

2012

  • Ankerst DP, Koniarski T, Liang Y, Leach RJ, Feng Z, Sanda MG, Partin AW, Chan DW, Kagan J, Sokoll L, Wei JT, Thompson IM. Updating risk prediction tools: a case study in prostate cancer. Biom J. 2012 Jan;54(1):127-42.
    [ PubMed Abstract ]
  • Feng Z, Kagan J, Pepe M, Thornquist M, Rinaudo JA, Dahlgren J, Krueger K, Zheng Y, Patriotis C, Huang Y, Sorbara L, Thompson I, Srivastava S. The Early Detection Research Network's Specimen Reference Sets: Paving the Way for Rapid Evaluation of Potential Biomarkers. Clin Chem. 2012 Nov 27. [Epub ahead of print] PubMed PMID: 23193062.
    [ PubMed Abstract ]
  • Kralj, Jason G, Arya, Chandamany, Tona, Alessandro, Forbes, Thomas P, Munson, Matthew S, Sorbara, Lynn, Srivastava, Sudhir and Forry, Samuel P. A simple packed bed device for antibody labelled rare cell capture from whole blood. Lab Chip, 2012, 12, 4972-4975.
    [ PubMed Abstract ]
  • Liu T, Hossain M, Schepmoes AA, Fillmore TL, Sokoll LJ, Kronewitter SR, Izmirlian G, Shi T, Qian WJ, Leach RJ, Thompson IM, Chan DW, Smith RD, Kagan J, Srivastava S, Rodland KD, Camp DG 2nd. Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J Proteomics. 2012 Aug 3;75(15):4747-57.
    [ PubMed Abstract ]
  • Prensner JR, Chinnaiyan AM, Srivastava S. Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis. 2012 Oct;29(7):645-52.
    [ PubMed Abstract ]
  • Wagner PD, Srivastava S. New paradigms in translational science research in cancer biomarkers. Transl Res . 159:343-53, 2012.
    [ PubMed Abstract ]

2011

  • Baum BJ, Yates JR 3rd, Srivastava S, Wong DT, Melvin JE. Scientific Frontiers: Emerging Technologies for Salivary Diagnostics. Adv Dent Res. 2011 Oct;23(4):360-8.
    [ PubMed Abstract ]
  • Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens. Cancer Prev Res (Phila). 2011 Mar;4(3):365-74.
    [ PubMed Abstract ]
  • Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC Jr, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 4(3): 375-83, 2011.
    [ PubMed Abstract ]

2010

    • Atha DH, Manne U, Grizzle WE, Wagner PD, Srivastava S, Reipa V. Standards for Immunohistochemical Imaging: A protein reference device for biomarker quantitation. J Histochem and Cytochem. 58:1005-14, 2010.
      [ PubMed Abstract ]
    • Baird CL, Fischer CJ, Pefaur NB, Miller KD, Kagan J, Srivastava S, Rodland KD. Developing recombinant antibodies for biomarker detection. Cancer Biomark. 2010;6(5-6):271-9.
      [ PubMed Abstract ]
    • Dunn BK, Wagner PD, Anderson D, Greenwald P. Molecular Markers for Early Detection. Semin Oncol. 37:224-242, 2010.
      [ PubMed Abstract ]
    • Grizzle WE, Srivastava S, Manne U. The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark. 2010;9(1-6):21-39.
      [ PubMed Abstract ]
    • Grizzle WE, Srivastava S, Manne U. Translational Pathology of Neoplasia. Cancer Biomark. 2010;9(1-6):7-20.
      [ PubMed Abstract ]
    • Patriotis, C., Maruvada, P. and Srivastava, S. Molecular Detection and Diagnosis of Cancer . In: The Molecular Basis of Human Cancer, 2 nd Edition. Humana Press.  2010.
    • Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, Chan DW. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1193-200.
      [ PubMed Abstract ]
    • Srivastava S, Grizzle WE. Biomarkers and the genetics of early neoplastic lesions. Cancer Biomark. 2010;9(1-6):41-64.
      [ PubMed Abstract ]
    • Wang W, Srivastava S. Noncoding RNAs in molecular characterization of cancer preneoplasia. Cancer Biomark. 2010;9(1-6):133-40.
      [ PubMed Abstract ]
    • Wang W, Srivastava S. Strategic approach to validating methylated genes as biomarkers for breast cancer. Cancer Prev Res (Phila Pa). 2010;3(1):16-24. 136.
      [ PubMed Abstract ]

    2009

    • Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009 137(1):110-8.
      [ PubMed Abstract ]
    • Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009 Jan;8(1):113-7.
      [ PubMed Abstract ]
    • Xiao Y, Gao X, Taratula O, Treado S, Urbas A, Holbrook RD, Cavicchi RE, Avedisian CT, Mitra S, Savla R, Wagner PD, Srivastava S, He H. Anti-HER2 IgY antibody-functionalized single-walled carbon nanotubes for detection and selective destruction of breast cancer cells. BMC Cancer. 2009 Oct 2;9:351.
      [ PubMed Abstract ]

    2008

    • Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark. 2008;4(1):19-33.
      [ PubMed Abstract ]
    • Jakupciak JP, Maggrah A, Maragh S, Maki J, Reguly B, Maki K, Wittock R, Robinson K, Wagner PD, Thayer RE, Gehman K, Gehman T, Srivastava S, Ngom A, Dakubo GD, Parr RL. Facile whole mitochondrial genome sequencing from nipple aspirate fluid using MitoChip v2.0. BMC Cancer. 2008 Apr 10;8:95.
      [ PubMed Abstract ]
    • Maki J, Robinson K, Reguly B, Alexander J, Wittock R, Aguirre A, Diamandis EP, Escott N, Skehan A, Prowse O, Thayer RE, Froberg MK, Wilson MJ, Maragh S, Jakupciak JP, Wagner PD, Srivastava S, Dakubo GD, Parr RL. Mitochondrial genome deletion aids in the identification of both false and true negative prostate needle core biopsies. Am J Clin Pathol. 2008 Jan;129(1):57-66.
      [ PubMed Abstract ]
    • Maragh S, Jakupciak JP, Wagner PD, Rom WN, Sidransky D, Srivastava S, O'Connell CD. Multiple strand displacement amplification of mitochondrial DNA from clinical samples. BMC Med Genet. 2008 Feb 7;9:7.
      [ PubMed Abstract ]
    • McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem. 2008 Jan;54(1):44-52.
      [ PubMed Abstract ]
    • McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem. 2008 Jan;54(1):53-60.
      [ PubMed Abstract ]
    • Seurynck-Servoss SL, Baird CL, Miller KD, Pefaur NB, Gonzalez RM, Apiyo DO, Engelmann HE, Srivastava S, Kagan J, Rodland KD, Zangar RC. Immobilization strategies for single-chain antibody microarrays. Proteomics. 2008 Jun;8(11):2199-210.
      [ PubMed Abstract ]
    • Srivastava S. Biomarkers at a Crossroads: Implications for Early Cancer Detection & Diagnosis Exit Disclaimer. In: IARC World Cancer Report, Section 3: Mechanism of Carcinogenesis, 2008;236-239.
    • Srivastava S, Krueger KE. Diagnostics other than blood. In: Wong, D editor. Saliva Diagnostics. Ames, Iowa: Blackwell Publishing; 2008;94-103.
    • Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW. [-2]proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute Early Detection Research Network Validation Study. J Urol. 2008 Aug;180(2):539-43; discussion 543.
      [ PubMed Abstract ]
    • Xiao Y, Gao X, Gannot G, Emmert-Buck MR, Srivastava S, Wagner PD, Amos MD, Barker PE. Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. Int J Cancer. 2008 May 15;122(10):2178-86.
      [ PubMed Abstract ]

    2007

    • Kagan J, Srivastava S, Barker PE, Belinsky SA, Cairns P. Towards clinical application of methylated DNA sequences as cancer biomarkers: a joint NCI's Early Detection Research Network and NIST workshop on standards, methods, assays, reagents and tools. Cancer Res. 2007 May 15;67(10):4545-9.
      [ PubMed Abstract ]
    • Srivastava S, Wagner PD. Risk-based and diagnostics-linked personalized medicine for cancer. Person Med. 2007 4:33-43.

    2006

    • Barker PE, Wagner PD, Stein SE, Bunk DM, Srivastava S, Omenn GS. Standards for plasma and serum proteomics in early cancer detection: A needs assessment report from the NIST-NCI SMART Workshop, August 18-19, 2005. Clinical Chem. 2006 Sep;52(9):1669-74.
      [ PubMed Abstract ]
    • Krueger KE. The potential of serum proteomics for detection of cancer: promise or only hope? Onkologie. 2006 Nov;29(11):498-9.
      [ PubMed Abstract ]
    • Krueger KE, Srivastava S. Posttranslational protein modifications: Current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics. 2006 Oct;5(10):1799-810.
      [ PubMed Abstract ]
    • Krueger KE, Srivastava S. Biomarkers. In: Rom WN editor. Environmental and Occupational Medicine, 4th edition. Philadelphia (PA): Lippincott Williams & Wilkins; 2006:109-20.
    • Maruvada P, Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1078-82.
      [ PubMed Abstract ]
    • McGruder BM, Atha DH, Wang W, Huppi K, Wei WQ, Abnet CC, Qiao YL, Dawsey SM, Taylor PR, Jakupciak JP. Real-time telomerase assay of less-invasively collected esophageal cell samples. Cancer Lett. 2006 Nov 28;244(1):91-100.
      [ PubMed Abstract ]
    • Srivastava S. Molecular screening of cancer: the future is here. Mol Diagn Ther. 2006;10(4):221-30.
      [ PubMed Abstract ]

    2005

    • Jakupciak JP, Barker PE, Wang W, Srivastava S, Atha DH. Preparation and characterization of candidate reference materials for telomerase assays. Clin Chem. 2005 Aug;51(8):1443-50.
      [ PubMed Abstract ]
    • Jakupciak JP, Wang W, Markowitz ME, Ally D, Coble M, Srivastava S, Maitra A, Barker PE, Sidransky D, O'Connell CD. Mitochondrial DNA as a cancer biomarker. J Mol Diagn. 2005 May;7(2):258-67.
      [ PubMed Abstract ]
    • Manne U, Srivastava RG, Srivastava S. Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today. 2005 Jul 15;10(14):965-76.
      [ PubMed Abstract ]
    • Maruvada P, Wang W, Wagner PD, Srivastava S. Biomarkers in molecular medicine: cancer detection and diagnosis. Biotechniques. 2005 Apr;Suppl:9-15.
      [ PubMed Abstract ]
    • Srivastava S. Cancer biomarkers: an emerging means of detecting, diagnosing and treating cancer. Cancer Biomark. 2005 1(1):1-2.
      [ PubMed Abstract ]
    • Srivastava S, Srivastava RG. Proteomics in the forefront of cancer biomarker discovery. J Proteome Res. 2005 Jul-Aug;4(4):1098-103.
      [ PubMed Abstract ]
    • Srivastava S, Verma M, Gopal-Srivastava R. Proteomic maps of the cancer-associated infectious agents. J Proteome Res. 2005 Jul-Aug;4(4):1171-80.
      [ PubMed Abstract ]
    • Wagner PD, Srivastava S. The Promise of Proteomics: Biology, Applications and Challenge. In: Srivastava S, editor. Informatics and Proteomics. CRC Press. 2005; p. 1-17.

    2004

    • Barker PE, Wang W, Wagner PD, Pinsky P. Inter-rater agreement on chromosome 5 breakage in FISH-based mutagen sensitivity assays (MSAs). Mutat Res. 2004 Aug 8;562(1-2):133-42.
      [ PubMed Abstract ]
    • Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist MD, Verma M, Zhang Z, Zou Z. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers. 2003-2004; 19(4-5):185-95.
      [ PubMed Abstract ]
    • Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, Adam BL, Troyer D, Srivastava S, Thornquist M, Zhang Z, Thompson IM. The Early Detection Research Network surface-enhanced laser desorption and ionization prostate cancer detection study: a study in biomarker validation in genitourinary oncology. Urol Oncol. 2004 Jul-Aug;22(4):337-43.
      [ PubMed Abstract ]
    • Habis AH, Vernon SD, Lee DR, Verma M, Unger ER. Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):492-6.
      [ PubMed Abstract ]
    • Jakupciak JP, Wang W, Barker PE, Srivastava S, Atha DH. Analytical validation of telomerase activity for cancer early detection: TRAP/PCR-CE and hTERT mRNA quantification assay for high-throughput screening of tumor cells. J Mol Diagn. 2004 Aug;6(3):157-65.
      [ PubMed Abstract ]
    • Maruvada P, Srivastava S. Biomarkers for cancer diagnosis: implications for nutritional research. J Nutr. 2004 Jun;134(6 Suppl):1640S-1645S.
      [ PubMed Abstract ]
    • Ravichandran V, Vasquez GB, Srivastava S, Verma M, Petricoin E, Lubell J, Sriram RD, Barker PE, Gilliland GL. Data standards for proteomics: mitochondrial two-dimensional polyacrylamide gel electrophoresis data as a model system. Mitochondrion. 2004 May;3(6):327-36.
      [ PubMed Abstract ]
    • Verma M, Maruvada P, Srivastava S. Current approaches in mitochondrial proteomics. Mito Matters. 2004 3(3-5).
    • Verma M, Maruvada P, Srivastava S. Epigenetics and cancer. Crit Rev Clin Lab Sci. 2004 41(5-6):585-607.
      [ PubMed Abstract ]
    • Wagner PD, Maruvada P, Srivastava S. Molecular diagnostics: a new frontier in cancer prevention. Expert Rev Mol Diagn. 2004 Jul;4(4):503-11.
      [ PubMed Abstract ]

    2003

    • Atha DH, Miller K, Sanow AD, Xu J, Hess JL, Wu OC, Wang W, Srivastava S, Highsmith WE. High-throughput analysis of telomerase by capillary electrophoresis. Electrophoresis. 2003 Jan;24(1-2):109-14.
      [ PubMed Abstract ]
    • Rajeevan MS, Dimulescu IM, Vernon SD, Verma M, Unger ER. Global amplification of sense RNA: a novel method to replicate and archive mRNA for gene expression analysis. Genomics. 2003 Oct;82(4):491-7.
      [ PubMed Abstract ]
    • Verma M. Viral genes and methylation. Ann N Y Acad Sci. 2003 Mar;983:170-80.
      [ PubMed Abstract ]
    • Verma M, Dunn BD, Ross S, Jain P, Wang W, Hayes R, Umar A. Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention. Ann N Y Acad Sci. 2003 Mar;983:298-319.
      [ PubMed Abstract ]

    Back to top